Stueland Katherine

Stueland Katherine, CEO of an undisclosed company, has demonstrated a pronounced selling bias in her recent trading activity involving shares of WGS (GeneDx Holdings Corp.), according to SEC Form 4 filings. Over the past three months, she executed 17 sell transactions totaling approximately $6.5 million, with no offsetting purchases aside from a single $299,926 award acquisition on March 6, 2026. The sales occurred in multiple tranches, including five transactions on March 26 alone—ranging from $318,952 to $848,699—and three sales on March 4 exceeding $450,000 each. Earlier activity in January and December 2025 followed a similar pattern, with smaller but consistent disposals. The transactions suggest a sustained reduction in her WGS position, with the bulk of sales concentrated in March 2026. While the March 6 award indicates ongoing equity compensation, the scale of disposals—totaling $13.7 million in lifetime sell value against just $299,926 in buys—reflects a clear directional trend. The sales were executed at varying price points, with no single dominant transaction but rather a series of methodical reductions. The absence of recent buying activity, coupled with the frequency and size of sales, underscores a consistent divestment approach in her dealings with WGS shares.